DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION

• US 20100130597A1
• Filed: 07/03/2008
• Published: 05/27/2010
• Est. Priority Date: 07/06/2007
• Status: Abandoned Application

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture
• Inventors: Park, Sung Jun, Kim, Myung Kyung, Chung, Jay Hang
• Application Number:
  US12/667,840
• Publication Number:
  US 20100130597A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 33/32 Manganese; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The invention relates to new functions of the DNA-PKcs gene product in energy metabolism, brain function and physical fitness.

Claims

1. A method of inhibiting DNA-PKcs expression and/or activity in a mammal to increase mitochondrial numbers, to increase thermogenesis, to increase insulin sensitivity, to improve insulin signaling, to reduce blood glucose levels, to increase AMPK and PGC-1 alpha activities, to improve motor function, to improve memory and learning abilities, to reduce depression and anxiety, to reduce inflammatory signaling, and/or to increase Sirt1, eNOS, VEGF and BDNF expression, the method comprising

administering to the mammal a therapeutically effective amount of an inhibitor of DNA-PKcs activity

to reduce weight in the mammal, to increase mitochondrial numbers, to increase thermogenesis, to increase insulin sensitivity, to improve insulin signaling, to reduce blood glucose levels, to increase AMPK and PGC-1 alpha activities, to improve motor function, to improve memory and learning abilities, to reduce depression and anxiety, to reduce inflammatory signaling and/or to increase Sirt1, eNOS, VEGF and BDNF expression in the mammal.

2. The method of claim 1, which reduces weight in a mammal.

3. The method of claim 1, wherein the mammal is obese.

4. The method of claim 1, wherein the mammal is middle-aged.

5. The method of claim 2, wherein the mammal reduces weight by about 5% to about 20% relative to a control mammal that does not receive the inhibitor.

6. The method of claim 2, wherein the method reduces the mammal'"'"'s fat mass relative to a mammal that has not received the DNA-PKcs inhibitor.

7. The method of claim 6, wherein the mammal'"'"'s fat mass is reduced by about 5% to about 30% relative to a control mammal that does not receive the inhibitor.

8. The method of claim 1, wherein serum triglycerides and/or serum leptin levels are reduced in the mammal.

10. The method of claim 2, wherein the mammal does not significantly restrict calorie intake.

11. The method of claim 1, wherein the mammal can run about 1.25 to about 3 times farther before exhaustion than a mammal that did not receive the inhibitor.

12. The method of claim 1, wherein mitochondrial numbers increase in the mammal by about two-fold to about three-fold relative to a control mammal that does not receive the inhibitor.

13. The method of claim 1, wherein thermogenesis increases in the mammal.

14. The method of claim 13, wherein the thermogenesis increases the mammal'"'"'s body temperature.

15. The method of claim 14, wherein the mammal'"'"'s body temperature increases by about 0.1°

C. to about 1°

C. relative to a control mammal that does not receive the inhibitor.

16. The method of claim 1, wherein the method also increases oxygen usage in the mammal.

17. The method of claim 16, wherein oxygen usage increases by about 5% to about 20% relative to a control mammal that does not receive the inhibitor.

18. The method of claim 1, wherein the method also increases AMPK, PPAR delta, CPT1b, UCP3, ERR alpha, VEGF, Sirt1, eNOS, PGC-1 alpha and/or PGC-1 beta expression in the mammal.

19. The method of claim 1, wherein the method improves the mammal'"'"'s stamina during physical activity.

20. The method of claim 19, wherein the mammal can run about 1.25 to about 3 times farther before exhaustion than a mammal that did not receive the inhibitor.

21. The method of claim 1, wherein ATP levels are higher in the mammal relative to a control mammal that does not receive the inhibitor.

22. The method of claim 21, wherein ATP levels are higher by about 5% to about 30% relative to a control mammal that does not receive the inhibitor.

23. The method of claim 1, wherein the method also reduces blood pressure.

24. The method of claim 23, wherein blood_pressure is reduced by about 10 mm Hg to about 30 mm Hg.

25. The method of claim 1, wherein insulin sensitivity and/or insulin signaling is increased in the mammal.

27. The method of claim 25, wherein glucose levels are lower in the mammal after insulin treatment than in a control mammal that does not receive the inhibitor.

28. The method of claim 25, wherein glucose levels are about 5% to about 40% lower in the mammal after insulin treatment than in a control mammal that does not receive the inhibitor.

29. The method of claim 1, wherein memory and/or learning ability are improved in a mammal.

30. The method of claim 29, wherein the mammal remembers where a target object is located better than a control mammal that did not receive the inhibitor.

31. The method of claim 29, wherein the mammal remembers where a target object is located about 50% to about 100% better than a control mammal that did not receive the inhibitor.

32. The method of claim 29, wherein brain-derived neurotrophic factor (BDNF) expression is increased in the mammal.

33. The method of claim 32, wherein brain-derived neurotrophic factor (BDNF) expression is increased in the mammal by about 10% to about 40% relative to a control mammal that did not receive the inhibitor.

34. The method of claim 1, wherein depression and/or anxiety is reduced in the mammal.

35. The method of claim 34, wherein the mammal engages in less anxiety-related food over-consumption.

36. The method of claim 35, wherein the mammal consumes of about 20% to about 80% less high fat food.

37. The method of claim 1, wherein the mammal is resistant to pain.

38. The method of claim 37, wherein the mammal resists pain about 10% to about 40% longer relative to a control mammal that did not receive the inhibitor.

39. The method of claim 1, wherein inflammation and/or inappropriate immune responses are reduced in the mammal.

40. The method of claim 39, wherein macrophage numbers are reduced in the mammal.

41. The method of claim 40, wherein macrophage numbers are reduced in the mammal'"'"'s adipose tissue.

42. The method of claim 39, wherein macrophage numbers are reduced in the mammal by about 40% to about 80%.

43. The method of claim 1 wherein heart disease is reduced in the mammal.

44. The method of claim 43, wherein the mammal is middle-aged or older.

45. The method of claim 43, wherein levels of reactive oxygen species are reduced in the mammal.

46. The method of claim 45, wherein levels of reactive oxygen species are reduced in the mammal'"'"'s heart by about 5% to about 50%.

47. The method of claim 43, wherein the mammal'"'"'s blood pressure is reduced.

48. The method of claim 47, wherein the mammal'"'"'s blood pressure is reduced by about 10 mm Hg to about 30 mm Hg.

49. The method of claim 1, further comprising treating or inhibiting a neurological disorder in a mammal.

50. The method of claim 49, wherein the neurological disorder is Alzheimer'"'"'s, Parkinson'"'"'s, Huntington'"'"'s disease, Amyotropic lateral sclerosis (ALS) or Friedreich ataxia (FRDA).

51. The method of any one of claims 1-50 wherein the inhibitor is NU7026 (2-(morpholin-4-yl)-benzo[h]chomen-4-one), Euk-134, Manganese (111) tetrakis(4-benzoic acid)porphyrin (MnTBAP), 2,4-dinitrophenol (DNP), a nucleic acid that can inhibit the expression and/or translation of DNA-PKcs, a chromen-4-one compound or any combination thereof.

52. The method of claim 51, wherein the inhibitor is combined with resveratrol, metformin, thiazolidinediones (TZD), Epigallocatechin gallate (EGCG), IC60211 (2-hydroxy-4-morpholin-4-yl-benzaldehyde), IC86621 (a methyl ketone derivative of IC60211), IC486154, IC87102, IC87361, Wortmannin, LY294002, or any combination thereof.

53. The method of claim 5I, wherein the nucleic acid that can inhibit the expression and/or translation of DNA-PKcs can hybridize to a nucleic acid having SEQ ID NO:

2 under physiological conditions.

54. The method of claim 51, wherein the nucleic acid that can inhibit the expression and/or translation of DNA-PKcs can hybridize to a nucleic acid having SEQ ID NO:

2 under stringent hybridization conditions.

55. The method of claim 51, wherein the nucleic acid that can inhibit the expression and/or translation of DNA-PKcs is a small interfering RNA (siRNA) or a ribozyme.

56. The method of any of claims 1-55, wherein the DNA-PKcs inhibitor is one or more compounds having formula I:

R₁—

Ar—

R₂(R₃)_n  

 

I

wherein;

R₁ is a hydrogen, lower alkoxy, cycloaryl, cycloheteroaryl, cycloalkyl or cycloheteroalkyl, wherein the cycloaryl, cycloheteroaryl, cycloalkyl and cycloheteroalkyl can optionally be substituted with one to four substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower alkoxy, cyano, aryl, and heteroaryl;

Ar is cycloaryl or cycloheteroaryl that can optionally be substituted with one or two oxy (═

O) or thio (═

S or —

SH) groups;

R₂ is cycloheteroaryl or cycloheteroalkyl;

R₃ is halo, lower alkyl, lower alkoxy, cyano, aryl, and heteroaryl; and

n is an integer of 0-3.

57. The method of claim 56, wherein R₁ is hydrogen,

58. The method of claim 56, wherein Ar is selected from the group consisting of:

59. The method of claim 56, wherein R₂ is selected from the group consisting of:

60. The method of any of claims 1-55, wherein the inhibitor is one or more of the compounds of formula II:

61. The method of any of claims 1-55, wherein the inhibitor is one of the following compounds or a combination thereof:

9. The method of claim 9, wherein the serum triglycerides and/or serum leptin levels are reduced by about 5% to about 70% in the mammal relative to a control mammal that does not receive the inhibitor.

26. The method of claim 26, wherein insulin levels are lower in the mammal by about 10% to about 50% relative to a control mammal that does not receive the inhibitor.